In the Perspective article in the March issue of Cellular and Molecular Gastroenterology and Hepatology,1 the Cytosponge erroneously was cited during the publication process as a Medtronic device (Medtronic, Minneapolis, MN). We would like to clarify that all published studies on Cytosponge to date have been performed using a research design patented by the Medical Research Council UK and made by local manufacturers and performed under permission from the Medical Health Regulatory Agency of the United Kingdom. This prototype device currently is being used in a 9000-patient primary care study in the United Kingdom (Barrett's ESophagus Trial 3 [BEST3]; trial ID ISRCTN68382401). This important study takes major steps to improve care for patients with Barrett’s esophagus.